Sid O’Bryant, PhD, Institute for Translational Research at UNT Health, Fort Worth, TX, discusses the Health & Aging Brain Study (HABS-HD), a robust brain aging study among diverse communities, with the goal of understanding brain health and aging to achieve precision medicine. Dr O’Bryant highlights that the study’s findings show the presence, progression, and clinical impact of Alzheimer’s biomarkers vary between groups, underscoring the importance of considering sociocultural, environmental, and medical comorbidities in understanding brain aging and Alzheimer’s disease. This interview took place at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
